About Us

Everything began with a question
"Is it possible to change the way people monitor their health?"
A Highly Specialized Molecular Testing Company based on Co-Operation
Since genomic testing is expensive and risky for smaller labs,
GTC was established as a cooperative to support smaller labs internalizing
next-gen sequencing (NGS) with AI to help localize cancer care.
Previous slide
Next slide


What Is GTC

Genomic Testing Cooperative (GTC) is a different kind of cancer diagnostic laboratory. Our cooperative model allows us to partner with laboratories, hospitals, oncology practices and medical professionals to share resources which create efficiencies in cost, turnaround time and quality. In creating a network of Co-Op partners, we help get results to physicians faster, share knowledge and generate better outcomes for patients.

Our testing is focused on comprehensive profiling of DNA and RNA in hematologic neoplasms and solid tumors, embracing the latest sequencing technology and informatics tools; providing better insights into the patient’s tumor signature. Our RNA sequencing capabilities go beyond just the detection of fusions and include alternative splicing, gene expression and prediction. Our RNA profiling can be used to compliment flow cytometry and immunohistochemistry (IHC) testing. GTC’s capabilities include liquid biopsy testing that give physicians testing options when tissue or bone marrow isn’t available. The informatics tools we use utilize artificial intelligence with sophisticated algorithms to interpret complex data sets, these informatics tools are unmatched anywhere on the market today.

GTC was founded in 2018 by Maher Albitar, MD who has held senior roles at numerous diagnostic laboratories and was a tenured professor at MD Anderson Cancer Center. He has committed his life to helping cancer patients by advancing cancer diagnostics and democratizing testing. Dr. Albitar founded GTC because he had a vision to revolutionize diagnostics and scientific discovery by improving access to comprehensive genomic profiling with next generation sequencing. He believes every cancer patient should have access to comprehensive genomic profiling. Dr. Albitar is regularly published in the top medical journals in oncology and has over 300 publications and authored over 50 patents.


We offer advanced genomic profiling for both solid and hematologic cancers to communities everywhere at an affordable price.

GTC utilizes a cooperative business model to help physicians treat patients locally with the most advanced precision medicine made possible by advanced diagnostic information.

We embrace disruptive technology and deep learning to create scalable efficiencies, incomparable precision, and a more personalized approach to patient care.


We are committed to driving the field of oncology forward by enabling more patients to contribute their unique cancer experience to the growing body of cancer genomics data.

We are committed to fulfilling precision medicine’s promise of individualized care for everyone by empowering physicians to formulate treatments that best suit each patient’s unique genetic profile.
November, 2018
November, 2018

GTC opens

Genomics Testing Cooperative is established.

June, 2019
June, 2019

Medicare coverage

GTC tests receive coverage decision from Medicare (Palmetto GBA) for all its tests including liquid biopsies
May, 2020
May, 2020

GTC partners
with JTCC

GTC partners with John Theuer Cancer Center/RCCA to open genomics laboratory

July, 2020
July, 2020

GTC partners with HMH

GTC partners with Hackensack Meridian Health to open genomics laboratory

March, 2021
March, 2021

Anthology Diagnostics opens

Anthology Diagnostics opens in collaboration with Hackensack Meridian Health

May, 2021
May, 2021

Key Genomics opens

New lab at John Theurer Cancer Center

June, 2021
June, 2021

NY State Approval

GTC Completes NY State Approval and Medicare (Palmetto) Coverage for all DNA and RNA Tests

May, 2022
May, 2022

Received CE Mark

GTC's testing is well validated with our menu receiving numerous accreditations including Medicare approval, NY State and CE Mark.



GTC Credentials


5 Reasons

that make GTC Unique
Monitoring Health
Diagnosis & Classifications
Selecting Therapy (CDX)
Predicting Prognosis
Monitoring Therapy
GTC Tests

Our Aim

is to offer you
Precision Medicine
Immune Profiling
Genetic Predisposition
Learn More


Machine / Deep Learning (AI) is the center of our analysis

Technology Innovations

Transforming Diagnostic Testing

• Accurate variant calling

• Increased efficiency

• Easier Interpreting of NGS data

•More accurate diagnosis, prognosis and clinical prediction

• Treatment recommendations

•Include new therapeutic approvals
•Clinical trial matching

• Large data sets for training AI

GTC AI Neural Network.png